Sara Karlovitch | Authors

Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.


BLA for Beti-Cel in B-thalassemia Accepted for Priority Review by FDA

November 23, 2021

The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.